Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ospemifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 12/20 | 0.70 |
| ▸ | ESR2 known ✓ | Q92731 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | HTR6 | P50406 | 1/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.70 |
| ▸ | ESRRG | P62508 | 14/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ESRRB | O95718 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ospemifene SCHEMBL2231997 | 1.00 | LMNA (0.71) | LMNAHTR6ESR1CYP19A1ESR2 | |
| Ospemifene SCHEMBL948120 | 1.00 | LMNA (0.71) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL5737939 | 1.00 | LMNA (0.71) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL8362664 | 0.95 | ESR1 (0.79) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL8362668 | 0.95 | ESR1 (0.79) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL6373604 | 0.95 | LMNA (0.65) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL8362672 | 0.95 | ESR1 (0.79) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL6373608 | 0.95 | LMNA (0.65) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL5738281 | 0.95 | ESR1 (0.79) | LMNAHTR6ESR1CYP19A1ESR2 | |
| SCHEMBL5738276 | 0.95 | ESR1 (0.79) | LMNAHTR6ESR1CYP19A1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1021 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260060936-A1 | INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS | TECHNION RES & DEV FOUNDATION (IL) | 2026-03-05 | — | — | US | claimed |
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-12414924-B2 | Lasofoxifene treatment of breast cancer | DUKE UNIVERSITY (US) | 2025-09-16 | — | — | US | claimed |
| EP-4611748-A1 | COMBINATION THERAPY FOR TREATING CANCER | Scorpion Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250262214-A1 | INTERMITTENT DOSING REGIMEN FOR AZENOSERTIB IN TREATING CANCER | ZENO MANAGEMENT, INC. | 2025-08-21 | — | — | US | claimed |
| EP-4593824-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| EP-3784215-B1 | SOFT GEL CAPSULE COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR | PHARMATHEN SA (GR) | 2025-07-09 | — | — | EP | claimed |
| WO-2025122504-A1 | ESR1 MUTATIONS, ESR1 CO-OCCURRING MUTATIONS, AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| US-20220044819-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR THE TREATMENT OF BREAST CANCER | GENENTECH, INC. | 2022-02-10 | — | — | US | claimed |
| WO-2022026901-A2 | NK ANTAGONISTS FOR CONTRACEPTION | ACER THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | claimed |
| EP-1786408-A1 | USE OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR THE MANUFACTURE OF A PHARMACEUTICAL PREPARATION FOR USE IN A METHOD FOR THE TREATMENT OR PREVENTION OF ANDROGEN DEFICIENCY | Hormos Medical Ltd. (FI) | 2007-05-23 | — | — | EP | claimed |
| US-20060293294-A1 | Method for treatment or prevention of androgen deficiency | HORMOS MEDICAL CORPORATION (FI) | 2006-12-28 | — | — | US | claimed |
| WO-2006084937-A1 | METHOD FOR DIAGNOSING AND TREATING WOMEN WITH INCREASED RESPONSE TO HORMONAL REPLACEMENT THERAPY | LESKELAE HANNU-VILLE (FI) | 2006-08-17 | — | — | WO | claimed |
| WO-2006024689-A1 | USE OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR THE MANUFACTURE OF A PHARMACEUTICAL PREPARATION FOR USE IN A METHOD FOR THE TREATMENT OR PREVENTION OF ANDROGEN DEFICIENCY | HORMOS MEDICAL LTD. (FI) | 2006-03-09 | — | — | WO | claimed |
| EP-0900077-B1 | Use of a toremifene metabolite for lowering serum cholesterol level. | ORION CORP (FI) | 2002-02-06 | — | — | EP | claimed |
| US-6037379-A | Serum cholesterol lowering agent | ORION CORPORATION (FI) | 2000-03-14 | — | — | US | claimed |
| EP-0900077-A1 | SERUM CHOLESTEROL LOWERING AGENT | ORION-YHTYMÄ OY (FI) | 1999-03-10 | — | — | EP | claimed |
| WO-1997032574-A1 | SERUM CHOLESTEROL LOWERING AGENT | Orion-Yhtymä Oy (FI) | 1997-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069593-A1 | METHODS FOR TREATING CANCER | KRAS, NRAS, HRAS | ESR1 2349/4885ESR2 3063/4885LMNA 2480/4885 |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | ESR1 99/4885ESR2 55/4885LMNA 1601/4885 |
| US-20260060936-A1 | INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS | CHRM1, CHRNA6, OPRM1 | ESR1 4497/4885ESR2 3917/4885LMNA 1116/4885 |
| US-20250262214-A1 | INTERMITTENT DOSING REGIMEN FOR AZENOSERTIB IN TREATING CANCER | ABL1, KRAS, JAK2 | ESR1 1262/4885ESR2 3322/4885LMNA 4421/4885 |
| US-20060293294-A1 | Method for treatment or prevention of androgen deficiency | SHBG, NR5A1, AR | ESR1 39/4885ESR2 33/4885LMNA 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.